Antimitotic colchicine possesses low therapeutic index due to high toxicity effects in nontarget cell. However, diverse colchicine analogs have been derivatized as intentions for toxicity reduction and structure-activity relationship (SAR) studying. Hybrid system of colchicine structure with nontoxic biofunctional compounds modified further affords a new entity in chemical structure with enhanced activity and selectivity. Moreover, nanocarrier formulation strategies have been used for colchicine delivery. This review paper focuses on colchicine nanoformulation, chemical synthesis of colchicine prodrugs and codrugs with different linkers, highlights linker chemical nature and biological activity of synthesized compounds. Additionally, classification of colchicine prodrugs based on type of conjugates is discussed, as biopolymers prodrugs, fluorescent prodrug, metal complexes prodrug, metallabile prodrug and bioconjugate prodrug. Finally, we briefly summarized the biological importance of colchicine nanoformulation, colchicine prodrugs and codrugs.
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A C C E P T E D ACCEPTED MANUSCRIPT polymerization, prompting tumour cells demise [5, 6] . Today, alongside its utilization in gout [7] , it is also utilized as a part of treatment familial Mediterranean fever [8, 9] , and in inflammatory disorder [10, 11] . Colchicine has applications in various illnesses like cirrhosis of bile and liver, and amyloidosis [12, 13] . It is found to be used in plants to separate chromosomes at metaphase and for multiplication, and in animals as selective neurotoxin to study Alzheimer's dementia [14, 15] .
Elucidation of the chemical structure of colchicine was a great achievement for scientists and their endeavours, particularly being developed for natural products chemistry. Zeisel began the investigation of colchicine structure , by determining the methoxy groups in colchicine. Windaus (1924) proposed a structure for colchicine based on phenantherene ring framework, and in 1940, Cohen proposed the B ring that is 7-membered. Then, in 1954, Dewar assumed C-ring had and aromatic character with a carbonyl group (cycloheptatrienolone), and this was a critical advancement to term another class of tropolones chemistry. X-ray analysis affirmed the correct structure of colchicine by King in 1952, and was approved by their chemical degradation [16, 17] .
The structure activity relationship (SAR) of colchicine binding to tubulin studied showed only compounds with (aS) axil chirality to be active. (-)-Colchicine was displayed to be active while (+)-colchicine 100-fold was less active. The trimethoxy moiety in ring (A) increased the affinity of colchicine binding to tubulin, and demethylation of ring (A) causes decrease of activity in the order of 1˃2˃3. A similar effect was observed for the methoxy moiety on tropolone ring (C). 2,3-methylenedioxy compound shows activity similar to colchicine. For ring (B), replacement of N-acetyl group with other alkyl amide results in no loss of activity, while N-alkyl groups are less active. The reversal of C-9/10 (iso compound) in ring C shows no activity at all and replacement of methoxy group on position 10 with group SMe or NR 2 results in increase of activity. The substitution of OH or H in position 10 showed decrease in activity but addition of ethyl substituents increased the activity.
Conversion of tropolone ring to phenyl ring results in a slight decrease in activity [5, 18] .
Capacity of colchicine to form tubulin-colchicine complex has been considered for anticancer activity [19] , but high toxicity of colchicine limited its medical application in cancer therapy [20] . Synthesis of colchicine derivative by modifying the basic structure with substituents has been made to decrease its toxicity and increase its therapeutic properties [19, [21] [22] [23] .
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Fluorescent colchicine as prodrug
The first fluorescent colchicine (FC) reported was on 1978 [44] , John Clark and Donita Garland prepared a colchicine conjugate with fluorescein core and isothiocyanate was used as linker. This conjugate maintains the specificity and biological activity of colchicine itself and provides a new strategy for relationships studying between cell functions and binding site of colchicine. Synthesis was started with deacetylation of colchicine using Wilson and Friedkin method to give isomers a mixture of deacetylcolchicine, iso-deactylcolchicine and lumi-deacetylcolchicine, which were separated by thin-layer chromatography (TLC) in acetone/methanol solvent system. Fluorescein isocthiocyanate was attached to deacetylcolchicine via condensation reaction and the product was purified with TLC ( Fig.   3A ). Excitation and emission fluorescein study showed no significant difference than fluorescein isocthiocyanate, at maximum 520 nm wavelength emission, spectrum showed a 490 nm excitation maximum for fluorescein isocthiocyanate compared to fluorescein (490 nm). At maximum 480 nm wavelength excitation, spectrum showed 521 nm emission maximum for fluorescein compared to fluorescein isocthiocyanate (521 nm). Biological assay showed that fluorescein colchicine conjugate did not impair the activity and specificity of colchicine itself. Toshiaki Hiratsuka and Toyoki Kato have reported the synthesis fluorescent derivative of N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-colcemid conjugate, (NBD-colcemid) [45] . Colcemid is colchicine structural analogue of N-deacetyl-N-methylcolchicine. Similar to colchicine, colcemid has high specificity and affinity to interfere with microtubules. Although NBD is fluorophore that has been used as fluorescent for studying protein conformational changes, and is highly soluble in low polarity solvents and low soluble in water, the excitation and emission maximum ranges are 460-480 and 520-550 nm, respectively. They synthesized the conjugate in one step by reaction of methylamino group colcemid with NBD-F, which only reacted with secondary amines. The excitation and emission spectrum showed that the maximum peak when NBD-colcemid bound to tubulin appeared at 465 and 530, respectively. Therefore, this conjugate is useful for studying the interaction of colcemid with tubulin, in addition to studying the relationship of cell function with colcemid-binding site ( Fig. 3B ).
One of the earliest studies on fluorescent colchicine conjugate was reported by Arnold et al. [46] . They synthesized two probes designated colchicine-504 and colchicne-646, with pHindependent and photo stable properties by coupling deacetyl colchicine with BODIPY M A N U S C R I P T
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(Boron-Dipyrromethane) succinimidyl esters dyes in dimethylformamide ( Fig. 3 
B and D).
BODIPY have properties like photo-nonbleaching, good quantum yield, green to red excitation wavelengths and insensitive to environment. The authors used fluorescence polarization to measure binding of conjugates to tubulin after the solubility of conjugates in Phosphate-buffered saline (PBS) was determined as 32 µM for colchicine-504 and <10 µM for colchicine-646. Binding affinity of colchicine-504 and colchicine was higher than FC, at 5.8 µM for colchicine-504 and 7.6 µM for colchicine-646 compared to 14.5 µM for FC.
Biological assay studied on HeLa, HepG2, Raji and Vero cell lines showed colchicine-504 is a stronger tubulin inhibitor than colchicine-646 due to lower quantum yield and the cytotoxicity of conjugates was less than colchicine.
Biopolymer-colchicine as prodrug
Recently, Smith et al. [47] have reported the synthesis and in vitro evaluation of new peptide sequence-colchicine as prodrug with over 90 % purity. This peptide sequence includes Ala-Ala-Asn-Val-OH cleavable by cysteine protease legumain (mammalian asparaginyl (Asn) endopeptidase), which is a restricted substrate specific enzyme and found in endothelial and stromal cells as well as in tumour macrophage. This enzyme supports tumour progress by activating cathepsin B, H and L process. Although the author mentioned that legumain was found in colorectal cancer and in more aggressive tumour cells, at low pH, it is auto-activated from 56 kDa to 47/46 kDa intermediate forms, then converted to mature active legumain 36 kDa by other cysteine proteases. Both intermediate and mature forms are inhibited by endogenous type 2 cystatins. The synthesis started with connection tripeptide Ala-Ala-Asn with valine (Val) as linker. As this sequence has high lipophilicity, N on Ala terminal was protected with BOC protection group, followed by condensation reaction of tetrapeptide sequence with deacetylcolchicine in dimethylformamide (DMF) solvent. Deprotection of N-BOC was the last step using trifluoroacetic acid and dichloromethane. Purification of prodrug was done by preparative HPLC.
The authors also synthesized valyl colchicine in low yield (20%) by coupling deacetylcolchicine with protected N-BOC-Val-OH in dimethylformamide solvent, followed by N-BOC deprotection using trifluoroacetic acid in dichloromethane, the product was precipitated as yellow salt. Biological assay was made on M38L, HCT116, HEK293, M4C and SW620 colorectal cancer cell lines, which showed that the prodrug is more toxic to cells that contain more active legumain than others, in addition to cleavage of prodrug in vitro by [48] . Polyethylene glycol (PEG 5000 ) used to increase hydrophilicity and size of prodrug, hence helping in the penetration of tissues to target cells. Colchicine was first substituted with N-2-hydroxyacetyl moiety on N of C-ring as linker for prodrug, produced hydroxyl moiety of colchicine, then hydroxyl colchicine coupled with PEG acetic acid produced nanomedicine prodrug of polymeric colchicine with ester linker (Fig. S1B ).
The strategy to use polymeric nanomedicine as prodrug was to reduce the toxicity of colchicine and improve the solubility, which leads to a change in the tissue membrane and drug hydrolysed then delivered colchicine drug to the targeted site. Additionally, the authors have used N-2-hydroxypropinoyl moiety linker for prodrug alternative of N-2-hydroxyacetyl moiety [49] . Biological evaluation in vivo showed higher efficiency vascular disruption agent and less toxic of prodrug than colchicine itself, also using different linkers received the prodrugs to liposomes and the hydrolysis rate determined the kinetics of drugs in liposomes.
Johansson et al. have reported Glycopeptide dendrimers colchicine conjugate for drug delivery system [50] . Colchicine was loaded on glycopeptide dendrimers using thioacetamide linker ( Fig. S2 ). Biological assay has shown that colchicine-dendrimer conjugate delivered colchicine as an active drug to the targeted site after degradation of intracellular without binding to tubulin, which leads to an increase cytotoxicity and selectivity of the active drug. Another example on specific gene target prodrug was reported by van Rossenberg et al. [53] .
Colchicine-bioconjugate prodrugs
They synthesized targeted prodrug for hepatocyte gene receptor, by attaching colchicine with di-N α ,N ε -(5-(2-acetamido-2-deoxy-β-D-galactopyranosyloxy)pentanomido) lysine ligand, K(GalNAc) 2 , a high affinity ligand for asialglycoprotein receptor in liver cells. Disulfide bridge was used as linker and fluorescein isothiocyanate was connected to prodrug for confocal microscopy study. Biological assay has shown that the affinity of prodrug to receptor was 4.5 nM, and augmented polyplexed DNA transfection efficiency in parenchymal liver cells is 50 fold higher at concentration 1 nM. In addition, the prodrug was nontoxic and can be employed as vehicles to transfer hepatic nonviral gene ( Fig. S3 ).
Another example of hepatocyte-targeted prodrugs with colchicine has been reported by
Plourde et al. [54] . Colchicine was linked with asialoglycoprotein by disulfide linker in ratio of drug with asialoglycoprotein (ASOR) done in two ways, deacetylcolchcince was attached to S-S linker followed by coupling with ASOR, and attachment of S-S to ASOR then coupled with deacetylcolchicine. Biological studied showed that the conjugate compound has destroyed microtubule cells, consequently conjugate was delivered to intracellular receptor and hydrolysis released the active drug into cell target.
Triazole linker containing prodrugs of colchicine has been reported by Kuznetsova et al. [55] .
The authors have attached palmitic and oleic esters to colchicine and allocolchicine through triazole bridge at nano-sized level with 100 nm diameter. Prodrugs formulation ( Fig. S4-A) was formed to improve lipophilicity, reduce toxicity, and to deliver colchicine to the targeted site. Palmitic and oleic esters were used as transporter through cell membranes due to both esters possessing hydrophobic properties to lipid bilayer. Biological assays have shown lipophilic prodrugs have potential anti-proliferative activity; in addition, fast liposomal hydrolysis leads to rapid delivering of drug onto the targeted site.
An androgen receptor (AR) antagonist colchicine prodrug CCN was reported by Sharifi Nima et al. [56] . Bifunctional colchicine prodrug inhibits the function of AR in castrate-resistant prostate cancer (CRPC), using cyanonilutamide, in addition to tubulin function inhibition greater than colchicine. Rigid alkyne was used as linker to colchicine-cyanonilutamide (CCN), ( Fig. S4-B ). Cogan and Koch method was used to attach halo-alkyn-ol linker to cyanonilutamide, followed by coupling of deacetylcolchicine to alkynl-cyanonilutamide by Colchicine was linked to peptide on 10-OCH 3 , the prodrug showed high selectivity after cleavage by MMPs and greater activity on tubulin binding site. Additionally, novel colchicine prodrugs with dual inhibitors for tubulin-HDAC have designed by X. Zhang et al., [59] . Benzamide has been used as HDAC zinc-binding group (ZBG), and linked to C7 of colchicine with amine or amide linkage (Fig. 5C ). Biological evaluation of this hybrid system showed influential HDAC and tubulin inhibitor activity with potent cytotoxicity (IC 50 = 2-105 nM). Thomopoulou , P. et al. have reported a new colchicinoids triazole-amino acid prodrug series [60] . The prodrug was synthesized by click-chemistry method, the colchicine has derived with triazole linker at C-7, then conjugated with several amino acids derivatives through 1,3dipolar cycloaddition using Cu(I) as catalyst ( Fig. S5 ). Biological evaluation of prodrug series against tumor cell lines including Hela, A549, and SK MES 1, showed a potent activity. The presence of benzyl, and/or halo-groups in amino acid derivatives increased compounds activity. Although, the IC 50 cytotoxicity test showed a remarkable activity in three compounds (IC 50 ≤ 5 nM). This results improved the ability of compound for tubulin depolymerization.
ZYN-linker thiocolchicine prodrugs have been reported by Baker et al. [61] . ZYN-Linker synthetic lipid-like molecules were designed to be inserted into cell membranes and to increase drug delivery to cells. pH-dependent hydrazone and imine linkers were used, three prodrugs were synthesized ( Fig. S6 ) for SAR studies. In addition ZYN-linker was attached to thiocolchicine at different positions, one on ring A and another on C-7 position of ring B.
Biological evaluation displayed that slow release of drug in vitro was less active (100 time) than individual drug, but it was established that the prodrug was able to block cell on metaphase division after 10 minutes of injection.
A library of colchicine neoglycoside prodrugs were synthesized by Ahmed A. et al. [62] , the role for using neoglycoside that modified the ADMET (absorption, distribution, metabolism, excretion and toxicity ) property of drug by prompting its solubility, toxicity, pharmacology, recognition of target and action mechanism. Methoxyamine linker that was attached to deacetylcolchicine gave methoxyamine deacetylcolchicine, followed by conjugation with Dglucose in neoglycosylation reaction (chemoselective) using DMF/AcOH which yielded the S7 ). Biological study on cancer cell lines showed colchicine neoglycosides has less potency than normal colchicine at 10 µM level, which is similar to Palclitaxel and Doxorubicin range.
Cauda et al. have reported a nano-sphere of lipid bilayers with colchicine loaded with diameter of 50 nm [63] ; the sphere consists of supported lipid bilayer (SLB) functionalized with colloidal mesoporous silica (CMS), leading to a stable shell with hybrid system (SLB@CMS) as a factor to deliver drug in a successful way. Nano-sphere is employed to protect the drug before releasing it to the target site and decrease the toxicity of drug by the lipid bilayer boundary. The researchers prepared SLB on CMS using the method of solvent exchange. Biological evaluation displayed the efficiency of nano-sphere method for delivery of colchicine drug in an appropriate way through sphere diffusion in intracellular condition. One more Gd.DOTA-colchicine prodrug with different linker lengths of thiocyanate has been reported by Efthimiadou et al. [66] . The authors synthesized two prodrugs as Magnetic Resonance Image (MRI) contrast agents, starting with deacetylation of colchicine followed by amidation with 3-aminopropanoic acid, and finally coupling reaction of colchicine derivatives with p-SCN-Bn-DOTA-Gd gave conjugate Gd.DOTA-colchicine. The synthesis of the second prodrug was the same except amidation with 3-aminopropanoic acid method was dropped ( Fig. S8-B ). Compared to Gd-colchicinic acid prodrug, Gd-DOTA-colchicine showed micromolar cytotoxicity level against MCF-7 cells; however, relaxivity of colchicinic acid conjugate was less than colchicine conjugate, 13 and 3.83 mM -1 s -1 respectively. The length of prodrug plays an important role on cytotoxicity based on the comparison made above.
Colchicine-metal complexes prodrug
Colchicine-radiolabeled prodrug
To explore the metabolism, pharmacodynamics and actions of anti-cancer drugs, (Fig. 7) . Biological study showed higher uptake of drugs in tumor cell lines and good pharmacokinetic in vivo. 3 ] + prodrug with colchicine [68] . N-(acetyloxy)-2picolyamion (AOPA) has been to conjugated colchicine, then attached to [ 99m Tc(CO) 3 ] + ligand using carbonyl-methylene linker (Fig. S9 ). 99m Tc possesses significant physical M A N U S C R I P T
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properties (t 1/2 = 6 h, 89% abundance) and low cost contributes to extensive radionuclide applications [69] . Biological evaluation revealed higher cell uptake but slow clearance observed in normal organs, leading to further development in linker or in ligand.
The authors have reported in 2013 a novel cationic and hydrophilic complex of [ 99m Tc(CO) 3 (PA-TZ-CHC)] + prodrug with modified triazole linker to overcome slow clearance from normal organs [70] . Colchicine was deacylated then derivatized with 2-(2azidoethoxy)ethyl to give azido colchicine derivative, click reaction of azido-derivative with N-(pyridin-2-ylmethyl)prop-2-yn-1-amine, which produced PA-TZ-colchicine as ligand for complexation. Finally, the attachment of ligand with [ 99m Tc(CO) 3 (H 2 O) 3 ] + created the complex prodrug (Fig. S9 ). Biodistribution study showed good accumulation and higher uptake than 99m Tc(CO) 3 -AOPA colchicine, fast clearance from normal organs and the prodrug possesses hydrophilic and cationic properties which make it stable at room temperature.
One more 99m Tc-colchicine complex prodrug has been reported by Erfani that produced SIB-PEG 4 -colchicine (cold reference) and ATE-PEG 4 -colchicine (precursor), finally electrophilic iododestannylation reaction of cold reference with the precursor gave lipophilic and pure [ 131 I]SIB-PEG4-colchicine with moderate yield (Fig. 8A ). Biodistribution showed poor uptake and retention of tumor cells but fast clearance from normal organs. 68 Ga-labeled to DOTA-colchiceine and NOTA-colchiceine were reported by Satpati et al.
using p-SCN-benzene linker [75] , which showed hundredfold significant cytotoxicity on MCF-7 and T47D breast cancer cell lines, in addition to higher uptake on mice bearing fibrosarcoma tumors and fast clearance from normal organs ( Fig. 8B and 8C ). 
Colchicine codrug
Codrug or 'mutual prodrug' is defined as two or more identical or non-identical drugs bonded via covalent chemical linkage. It differs from prodrug in having an active group, a cleavable linker coupled both drugs directly or indirectly. However, codrug has limitation in the selection of a specific functional group for linkage. The codrug possesses a good absorption rate prime with effortless delivery to target site. After being hydrolyzed in gastrointestinal level it provides two or more different drugs without any shifting in therapeutic properties and it is desirable to be released concomitantly at the target site.
Another strategy of codrug has been built using a double drug, called hybrid drugs, where the two drugs are linked everlastingly without cleavable bond [78] [79] [80] .
Codrugs can be classified into two groups based on spacer: directly linked or indirectly linked codrugs. The rule of spacer in active drugs is either to increase chemical stability or to control M A N U S C R I P T
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the drug release, but codrugs have disadvantages in higher molecular weight and side effect associated in individual drugs. Therefore, the selection of spacer with some desired properties is also logical for codrug delivery system. In direct-coupling of codrug, the conjugation of both drugs was made by ester/amide bond and the most codrugs designed under this group [29, [81] [82] [83] [84] .
In the last decade, there has been a steady improvement in colchicine ADMET properties by the implementation of codrug strategy. Several colchicine codrugs systems have been developed. This section illustrates various colchicine codrugs that have been reported.
Zefirova et al. have reported synthesis of adamantane-colchicine codrug with
depolymerization and clustering of tubulin [85] . Adamantane is used as an antiviral drug for flu and is also used as a key structural subunit for drug design. Adamantane was coupled with colchicine using an amide linker with different lengths for SAR study (Fig. S11-A) .
Biological assays have shown that cytotoxicity increased by increasing the length of linker, and substitution on adamantane plays an important role on tubulin clustering. The authors again have reported that the synthesis of colchicine-tubuloclustin codrug (n=5) emerged unusual clustering of tubulin [86] .
Another colchicine codrug was synthesized as homodimer of colchicine and isocolchicine by
Funaioli et al. [87] . Colchicine and isocolchicine was coupled on C-10 and C-9 substituent respectively in Semmelhack's reaction where bis(cyclooctadiene) nickel(0) Ni(COD) 2 was used as a catalyst in DMF solvent. Homodimer of 10,10'-bicolchicine and 9,9'bisiocolchicine ( Fig. S11-B ) linked by a single covalent bond at absolute configuration (R a , 7S), bisiocolchicine produced as isomer of (R a ,7S) and (S a ,7'S). These have both hydrophilic and hydrophobic properties that made them easily soluble in polar and nonpolar solvents. UV and Circular Dichroism (CD) spectrums have shown that homodimer is solvent-dependent due to multichromophoric system and any changes in solvent mixtures changes the CD bands.
Bensel et al. have also reported the synthesis of homodimer of colchicine coupled on C-4 using methylene bridge linker [88] . The reaction was done with formaldehyde in H 2 SO 4 with heating at 50 ºC, which gave homodimer colchicine at low yield ( Fig. S11-B [89] . Paclitaxel (taxol) has a different tubulin-binding site from colchicine, its bind on (+) and (-) ends of microtubule, colchicine binds on the (+) end. Paclitaxel promotes microtubule polymerization and assembly but prevents free tubulin in the cell. Synthesis was started with deacetylation of colchicine in three steps reaction using Lebeau method, followed by amidation on N-deacetylated with glutaric anhydride in dimethylformamide (DMF) solvent, which produced N-glutaryl-deacteylcolchicine. Paclitaxel has two hydroxyl groups; a protection was made on less active -OH using tert-butyldimethylsilyl (TBDMS) ether, then two drugs were coupled using Postema and co-workers procedure [90] , deprotection of -OH was achieved by tetra-N-butylammonium fluoride (TBAF), which gave colchitaxel codrug (Fig. 9A ). Colchicine-Paclitaxel (Colchitaxel) compound in bio-assay has shown partial properties as single compounds, which also had affected the + end protein cap that caused fragmentation and shortening of the + end.
In addition, paclitaxel have been coupled with colchicine analoug, thiocolchicine, using succinate linker [91] . Danieli et al. have reported production of three paclitaxelthiocolchicine co-drugs with thiocolchicine linker connected at 10, 7 and 2-OH of paclitaxel ( Fig. 9B-9D ). The coupling was achieved via condensation reaction using 1,3dicyclohexylcarbodiimide (DCC) and 4-(dimethylamino)pyridine (DMAP).
Triethylsilane (TES) was used as protection group. In the case of using 10-OH in connection with N-succinate deacetylthiocolchicine, 13 and 7-OH on paclitaxel was protected with TES, the same was with 13-OH connection and 7-OH connection, while other OH was protected to prevent its contribution in reaction synthesis. Biological assay showed that 7-O-paclitaxolthiocolchicine and 10-O-paclitaxel-thiocolchicine compounds possess high cytotoxicity, 2-Opaclitaxel-thiocolchicine did not show any activity but had an obvious molecular target different from tubulin.
Another example on thiocolchicine codrug was also reported by Danieli et Al. [92] , where thiocolchicine was coupled with podophyllotoxin using disulfide linker (Fig. 10A ).
Podophyllotoxin is a pharmacological precursor used for treatment of etoposide cancer [93] . codrugs with uracil and 5-fluorouracil using amide linker [95] . Uracil is antitumor agent, also it's known as base of RNA [96] . 5-fluorouracil is one of anticancer drugs, has been used for treatment of several cancer cells including gastric head, neck, colorectal and stomach [97, 98] . Nonetheless, due to its side effect, it has limited in clinical application [99] . The synthesis started by conversion of colchicine into thiocolchicine in the presence of (Fig. 10B ).
Biological evaluation showed that synthesized compounds a significance antitumor activity against BEL7402, A2780, A549 and MCF7 cell lines, more than colchicine and 5fluorouracil itself.
A hybrid molecule of colchicine-pironetin analogue with ester linker have been reported by Vilanova et al. as gene expression inhibitor for VEGF, hTERT and c-Myc genes, which are important in the process of cancer generation [100] . Pironetin is an anticancer and tubulin inhibitor, able to pervert cell cycle progression by binding the tubulin at M-phase, specifically at Cys316 site of alpha tubulin [101] . VEGF gene used in angiogenic process, term to Vascular Endothelial Growth Factor. Whereas hTERT and c-Myc involved in telomerase activation. The biological evaluation showed codrug is being responsible for the activity (Fig. S12) .
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Nanoformulation of colchicine
Herbal drugs are mostly hydrophobic hence possess poorly absorbable property, this property leads to a greater dose with repeated administration during treatments result in a decrease in bioavailability and limitation in clinical use [102, 103] . Therefore, the trend to apply nanotechnology in herbal drug delivery has spread rapidly in the recent time [104] .
Drug delivery system (DDS) is capable to increase drug bioavailability and reduce the repeated administration by providing site targeting selectivity and sustained drug release, in addition to consent increasing of the patient [105] . Meanwhile, several commercial drugs have been formulated and easily accessible in the market. Those formulations have been applied using several drug delivery strategies such as microemulsion, polymeric nanoparticles, liposomes, liquid crystal, and microspheres [106] [107] [108] . 
Future Perspectives
The development in nanomedicine is rapidly growing at this time, especially for controlled released drug and sustained delivery. Moreover, due to the high surface area, biocompatibility, biodegradability, and non-toxicity of graphene oxide (GO), many researchers have used GO as a nanocarrier for an anticancer drug with a high potential activity and better selectivity to the target site. Specifically, when it is fabricated in a hydrogel matrix with a biopolymer, such as carboxymethyl cellulose, sodium alginate, chitosan and guar gum, those biopolymers possess excellent properties including watersoluble, biocompatible, and non-toxic. Applying graphene oxide hydrogel matrix as a nanocarrier for colchicine drug delivery either by the chemical or physical method will provide sustained drug delivery and give better result for cancer treatment.
Summary
In summary, colchicine prodrugs and codrugs have become an attractive part in drug 
